Abiopharma

🔍 McCoig Dain A (Executive)

Company: enCore Energy Corp. (EU)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 94,595 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: false | shares_owned_after: 94,595.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 141,892 shares of Performance Share Unit (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: false | shares_owned_after: 141,892.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one common share of enCore Energy Corp. (the "Company").
• F2: On August 17, 2026, the reporting person was granted 94,595 restricted stock units. The restricted stock units vest one-third on August 17, 2027, one-third on August 17, 2028 and one-third on August 17, 2029.
• F3: Each performance share unit represents the contingent right to receive one common share of the Company subject to performance objectives regarding total shareholder return performance of the Company measured against a peer group of uranium industry companies over a three-year performance period ending December 31, 2028. The number of performance share units represents the target number, and the reporting person may earn between 0% and 200% of the target number of performance share units.